Sutro Biopharma Inc (STRO) Stock Price, Quote & News

Company Profile

Sutro Biopharma, Inc. operates as a oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. The company also develops VAX-24 and Vax-31 pneu...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 881 6500

Fax: 650 553 9659

Website: www.sutrobio.com

Address:

111 Oyster Point Boulevard, South San Francisco, United States

betaino Jul. 14 at 12:26 PM

$STRO https://www.globalipnews.com/?industry=Pharmaceutical&key=1W

0 · Reply

ztocklydotcom Jul. 13 at 3:40 PM

$STRO A golden barcode detected with our patent-pending system. Still early in the backtesting stages, should have all the data needed by September to file for the patent. A golden barcode doesn’t mean something explosive is on the horizon, but potential energy releasing soon.

0 · Reply

KY3000 Jul. 13 at 3:15 PM

$STRO Huge biotech investor buys 4 Bay Area companies on brink of collapse https://www.sfgate.com/tech/article/fund-gobbling-bay-area-biotech-20761986.php

0 · Reply

Bbboston Jul. 11 at 12:12 PM

$STRO They have no sales now or anytime soon. They have to spend hundreds of millions on clinical trials which will take years. The cash they have in hand is what it is holding .80 otherwise this would be bankrupt or .10 cents a share at best. If they spend their money wisely, they will have chances to raise capital in the future as they develop their new drugs.

1 · Reply

KY3000 Jul. 9 at 10:47 PM

$STRO their using every PR for a selling event. Thats why it’s trash , stf already

0 · Reply

betaino Jul. 9 at 5:07 PM

$STRO https://www.linkedin.com/posts/sutro-biopharma-inc-_dual-payload-adcs-move-into-first-oncology-activity-7348748411308822528-31b5?utm_source=share&utm_medium=member_android&rcm=ACoAADXQ-CcB6bP4Ec7wuHXzSSdNskmMqXuLVTU

0 · Reply

jasgus Jul. 9 at 2:25 AM

$STRO full position complete. got a good feeling about this one. 3xxx

0 · Reply

KY3000 Jul. 7 at 8:39 PM

$STRO hedge buys 5% and the stock is down.mrkt cap 62$MILL with 249$ mill as of march 2025, no debt. Tute ownership 84%. Someone explain

0 · Reply

betaino Jul. 7 at 12:38 PM

$STRO https://www.boehringer-ingelheim.com/partnering/boehringer-ingelheim-bioxcellence/sutro-biopharma-collaboration-first-class-cell-free-capabilities

3 · Reply

Biotech_Beast Jul. 2 at 3:59 PM

$STRO Thoughts on management at this company?

3 · Reply

Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights

May 1, 2025, 4:05 PM EDT - 2 months ago

Sutro Biopharma to Participate in Upcoming Investor Conferences

Apr 28, 2025, 4:05 PM EDT - 2 months ago

Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025

Mar 15, 2025, 6:40 PM EDT - 4 months ago

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

Mar 14, 2025, 12:09 PM EDT - 4 months ago

Penny Stock Sutro Biopharma Cuts Costs, Refocuses Pipeline

Mar 13, 2025, 4:07 PM EDT - 4 months ago

Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights

Mar 13, 2025, 4:05 PM EDT - 4 months ago

Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline

Mar 3, 2025, 4:05 PM EST - 4 months ago

Sutro Biopharma to Present at the TD Cowen 45th Annual Health Care Conference

Jan 7, 2025, 4:05 PM EST - 6 months ago

Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 2, 2025, 6:28 PM EST - 6 months ago

Sutro Biopharma: I Don't Buy That Their Pipeline Is Worthless

Nov 13, 2024, 4:30 PM EST - 8 months ago

Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights

Nov 4, 2024, 4:05 PM EST - 9 months ago

Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference

Nov 1, 2024, 8:00 AM EDT - 9 months ago

Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML

Oct 10, 2024, 4:05 PM EDT - 9 months ago

Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum

Sep 23, 2024, 12:46 PM EDT - 10 months ago

Sutro Biopharma's Competitive ADCs Position It For Future Growth In Oncology

Sep 20, 2024, 4:01 PM EDT - 10 months ago

Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Sep 14, 2024, 3:00 AM EDT - 10 months ago

Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024

Sep 11, 2024, 8:00 AM EDT - 10 months ago

Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024

Aug 22, 2024, 8:00 AM EDT - 11 months ago

Sutro Biopharma Announces Initiation of REFRαME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer

Aug 13, 2024, 4:30 PM EDT - 1 year ago

Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

Jun 3, 2024, 10:00 AM EDT - 1 year ago

VGXI Inc. announces a strategic partnership with Sutro Biopharma Inc. to support growing clinical pipeline

May 13, 2024, 4:30 PM EDT - 1 year ago

Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

Apr 30, 2024, 8:00 AM EDT - 1 year ago

Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 Trial

Apr 5, 2024, 6:31 PM EDT - 1 year ago

Ipsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For Investors

Apr 2, 2024, 6:18 AM EDT - 1 year ago

Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering

Apr 2, 2024, 1:00 AM EDT - 1 year ago

Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors

Mar 25, 2024, 4:30 PM EDT - 1 year ago

Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones

Jan 4, 2024, 4:05 PM EST - 1 year ago

Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC

Dec 29, 2023, 4:11 PM EST - 1 year ago

Sutro: Luveltamab Data At ESMO Signifies Continued ADC Advancement

Dec 14, 2023, 4:05 PM EST - 1 year ago

Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024

$Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023$

Dec 11, 2023, 4:05 PM EST - 1 year ago

Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023

Dec 4, 2023, 4:05 PM EST - 1 year ago

Sutro Biopharma to Participate in the JMP Securities Hematology and Oncology Summit

Nov 21, 2023, 4:05 PM EST - 1 year ago

Sutro Biopharma Promotes Jane Chung to President and Chief Operating Officer

Nov 13, 2023, 4:30 PM EST - 1 year ago

Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

Oct 22, 2023, 4:25 AM EDT - 1 year ago

Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study in Endometrial Cancers at ESMO 2023

Oct 16, 2023, 4:05 PM EDT - 1 year ago

Sutro Demonstrates Meaningful ADC Innovation with Five Presentations and One Poster at the 14th Annual World ADC Conference

Oct 9, 2023, 9:48 AM EDT - 1 year ago

Sutro Biopharma: Luvelta Data For Endometrial Cancer Treatment Approaching

Sep 19, 2023, 8:00 AM EDT - 1 year ago

Sutro Biopharma Appoints Dr. Hans-Peter Gerber as Chief Scientific Officer

Sep 14, 2023, 1:21 PM EDT - 1 year ago

Sutro BioPharma: Good Stewardship Through Early Trials

Aug 10, 2023, 4:30 PM EDT - 2 years ago

Sutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

Jun 26, 2023, 8:00 AM EDT - 2 years ago

Sutro Biopharma and Blackstone Announce Royalty Financing Collaboration

Jun 3, 2023, 4:00 PM EDT - 2 years ago

Sutro Biopharma Announces Oral Presentation at ASCO 2023 Featuring Data for Luveltamab Tazevibulin from the Phase 1 Dose-Expansion Study in Ovarian Cancer and the Initiation of the Phase 2/3 Pivotal Study REFRaME-O1

May 31, 2023, 8:00 AM EDT - 2 years ago

Sutro Biopharma to Participate in the Jefferies Healthcare Conference

May 15, 2023, 8:00 AM EDT - 2 years ago

Sutro Biopharma Reports First Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

May 8, 2023, 8:00 AM EDT - 2 years ago

Sutro Biopharma to Present at the JMP Securities Life Sciences Conference

Apr 27, 2023, 4:30 PM EDT - 2 years ago

Sutro Biopharma Announces the Departure of President of Research & Chief Scientific Officer

Apr 18, 2023, 1:30 PM EDT - 2 years ago

Sutro Biopharma Presents Preclinical Data for its ROR1 Targeting Antibody Drug Conjugate STRO-003 at the AACR Annual Meeting 2023

Apr 11, 2023, 1:17 PM EDT - 2 years ago

Sutro: Too Little, Too Late For STRO-002, But Platform Is Interesting

Mar 30, 2023, 4:30 PM EDT - 2 years ago

Sutro Biopharma Reports Full Year 2022 Financial Results, Business Highlights and Select Anticipated Milestones

Mar 17, 2023, 4:01 PM EDT - 2 years ago

Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

betaino Jul. 14 at 12:26 PM

$STRO https://www.globalipnews.com/?industry=Pharmaceutical&key=1W

0 · Reply

ztocklydotcom Jul. 13 at 3:40 PM

0 · Reply

KY3000 Jul. 13 at 3:15 PM

$STRO Huge biotech investor buys 4 Bay Area companies on brink of collapse https://www.sfgate.com/tech/article/fund-gobbling-bay-area-biotech-20761986.php

0 · Reply

Bbboston Jul. 11 at 12:12 PM

1 · Reply

KY3000 Jul. 9 at 10:47 PM

$STRO their using every PR for a selling event. Thats why it’s trash , stf already

0 · Reply

betaino Jul. 9 at 5:07 PM

0 · Reply

jasgus Jul. 9 at 2:25 AM

$STRO full position complete. got a good feeling about this one. 3xxx

0 · Reply

KY3000 Jul. 7 at 8:39 PM

$STRO hedge buys 5% and the stock is down.mrkt cap 62$MILL with 249$ mill as of march 2025, no debt. Tute ownership 84%. Someone explain

0 · Reply

betaino Jul. 7 at 12:38 PM

$STRO https://www.boehringer-ingelheim.com/partnering/boehringer-ingelheim-bioxcellence/sutro-biopharma-collaboration-first-class-cell-free-capabilities

3 · Reply

Biotech_Beast Jul. 2 at 3:59 PM

$STRO Thoughts on management at this company?

3 · Reply

KY3000 Jul. 2 at 10:59 AM

$STRO another 52 week low coming, c-suite is trash

0 · Reply

theBigDollarski Jun. 30 at 7:08 PM

$STRO end of quarter..someone's liquidating today...good time to pick some shares up

0 · Reply

KY3000 Jun. 27 at 8:18 PM

$STRO 9 mill shares traded at close, I think we in trouble

1 · Reply

KY3000 Jun. 27 at 8:10 PM

$STRO this is ugly

0 · Reply

KY3000 Jun. 25 at 9:15 PM

$STRO -3x cash. Give $ back to shareholders, sell company. C suite purposely turned this into a zombie stock.

0 · Reply

SylusAtreau Jun. 25 at 8:40 PM

$STRO

0 · Reply

WhatGoesOn Jun. 20 at 12:30 PM

$STRO Someone's gonna wanna get at Luvelta eventually, probably sooner than later. That's when I get my money back!

0 · Reply

john714 Jun. 16 at 6:07 PM

$STRO Piper Sandler upgrades today to $2.00 price target.

0 · Reply

Finnisher2M Jun. 16 at 4:14 PM

$STRO Solid day here👍

0 · Reply

KY3000 Jun. 12 at 2:39 PM

$STRO -3x cash!?

0 · Reply

KY3000 Jun. 12 at 2:00 PM

$STRO trash, what is csuite doing?

0 · Reply

KY3000 Jun. 11 at 7:48 PM

$STRO what’s the point of this?, giving themselves free shares. Give $ back to shareholders and give up. I’m losing confidence in this, zombie biotech

0 · Reply

Market Cap	64.50M
Revenue (ttm)	62.04M
Net Income (ttm)	-227.46M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-366.63%
Debt to Equity Ratio	0.00

Volume	446,200
Avg Vol	1,123,540
Day's Range	N/A - N/A
Shares Out	84.46M
Stochastic %K	44%
Beta	1.64
Analysts	Sell
Price Target	$3.26